Cargando…

Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients

Objective: Capecitabine is an antimetabolic fluoropyrimidine deoxynucleoside carbamate drug that can be converted to 5-FU in vivo. Currently, the role of capecitabine in the treatment of advanced breast cancer has been recognized. Also, Several meta-analyses have elucidated the role of capecitabine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Di, Chen, Xiu, Li, Xingjiang, Mao, Zhixiang, Tang, Wenjuan, Zhang, Wei, Ding, Li, Tang, Jinhai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360291/ https://www.ncbi.nlm.nih.gov/pubmed/30719136 http://dx.doi.org/10.7150/jca.29739

Ejemplares similares

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
por: Dyar, Stephen, et al.
Publicado: (2011)

Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
por: Bi, Pingping, et al.
Publicado: (2023)

Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials
por: Yin, Weijiao, et al.
Publicado: (2015)

Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer
por: YUAN, MEIQIN, et al.
Publicado: (2014)

Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review
por: Xu, Weilin, et al.
Publicado: (2020)

Capecitabine for primary breast cancer
por: Toi, Masakazu, et al.
Publicado: (2017)

Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future
por: Chen, Xiu, et al.
Publicado: (2019)

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
por: Valerio, Maria Rosaria, et al.
Publicado: (2021)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017)

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
por: Tubiana-Mathieu, N, et al.
Publicado: (2009)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2016)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
por: Chen, Xue-Lian, et al.
Publicado: (2016)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
por: Chao, Yee, et al.
Publicado: (2014)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
por: Hackshaw, A, et al.
Publicado: (2005)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

Response of Cutaneous Metastases from Breast Cancer to Capecitabine
por: Sideras, Kostandinos, et al.
Publicado: (2008)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
por: Einbeigi, Z., et al.
Publicado: (2008)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
por: Ye, Feng, et al.
Publicado: (2022)

Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
por: Vernieri, Claudio, et al.
Publicado: (2020)

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
por: Chung, Kwang Hyun, et al.
Publicado: (2017)

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
por: Rak Tkaczuk, Katherine H.
Publicado: (2011)

Capecitabine and stereotactic radiation in the management of breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016)

Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report
por: Kawaguchi, Takashi, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_dq2c3bvrggd32ved4ln9uuculf